Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hemostatic Agent Clear all
Terminated Phase 2 Interventional Results available

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

NCT01720043
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Palatal Donor Site Wound Healing Following Periodontal Plastic Surgery Using Amnion-Chorion Membrane

NCT05927714
View directory record Official record
Conditions
Palate; Wound
Interventions
Amnion-chorion Membrane, ActCel Cellulose Gauze
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Cold Plasma for the Reduction of Lymphoceles Following PLND

NCT02658851
View directory record Official record
Conditions
Lymphoceles Following Pelvic Lymph Node Dissection
Interventions
J-Plasma
Device
Lead sponsor
Apyx Medical
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 18, 2026, 5:38 AM EDT
Completed No phase listed Observational

Hemostatic Profiles in Pediatric CKD

NCT05064267
View directory record Official record
Conditions
Kidney Disease, Chronic, Pediatric Kidney Disease, Renal Insufficiency, Chronic, Blood Coagulation Disorders in Children
Interventions
phlebotomy
Diagnostic Test
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 18, 2026, 5:38 AM EDT
Terminated Early Phase 1 Interventional

Liposomal Bupivicaine for Skin Graft Donor Sites in Burn Patients

NCT03705637
View directory record Official record
Conditions
Burns, Postoperative Pain
Interventions
Exparel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma

NCT01536496
View directory record Official record
Conditions
Acute Coagulopathy
Interventions
Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.
Biological
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

RAVE: Radial Artery Vascular Complication and Resource Utilization

NCT03522077
View directory record Official record
Conditions
Angiogram, Percutaneous Coronary Intervention
Interventions
RadAR EasyCLik plus ®-STF hemostatic pad, TR BAND® Compression device plus ®-STF hemostatic pad, SoftSeal®-STF hemostatic pad, VascBand™ Hemostat
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma

NCT04402632
View directory record Official record
Conditions
Subdural Hematoma
Interventions
Surgical Management, Onyx™ Liquid Embolic System (LES) Embolization, Observation Only
Procedure · Device · Other
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Phase 4 Interventional

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

NCT01095822
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aliskiren + Valsartan
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis

NCT00863356
View directory record Official record
Conditions
Epistaxis
Interventions
2009-I-Epistaxis-1
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

NCT03725098
View directory record Official record
Conditions
Cardiothoracic Surgery
Interventions
HEMOBLAST Bellows, FLOSEAL
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Not applicable Interventional Results available

U.S. Study of Fibrocaps in Surgical Hemostasis

NCT01256164
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Fibrocaps (fibrin sealant), Gelfoam
Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

NCT06095050
View directory record Official record
Conditions
Shoulder Pain, Tendinopathy, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis, Embolization, Arterial Occlusion
Interventions
Embolization, Physical Therapy
Device · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed No phase listed Observational

Triamcinolone Packing Following Endoscopic Sinus Surgery

NCT04841343
View directory record Official record
Conditions
Sinusitis
Interventions
Triamcinolone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Phase 3 Interventional

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

NCT01619046
View directory record Official record
Conditions
Hemophilia A
Interventions
GreenGene™ F and an approved recombinant Factor VIII product, GreenGene™ F
Biological
Lead sponsor
Green Cross Corporation
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2010 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

NCT02880163
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
Interventions
ResQFoam
Device
Lead sponsor
Arsenal Medical, Inc.
Industry
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 18, 2026, 5:38 AM EDT
Recruiting Phase 3 Interventional

Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression

NCT05058287
View directory record Official record
Conditions
Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
Interventions
Depo-Medrol 40Mg/Ml Suspension for Injection, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Modifications to Radical Prostatectomy

NCT01407263
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lymph node template, Transverse versus vertical closure, antibiotic prophylaxis, Hemostatic Agent
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
3,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Completed Phase 2 Interventional Results available

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

NCT03472586
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Ipilimumab, Nivolumab, Embolization Therapy
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 5:38 AM EDT
Not listed Phase 3 Interventional

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

NCT06143787
View directory record Official record
Conditions
Bleeding From Teeth, Bleeding Prophylaxis
Interventions
Tranexamic acid
Drug
Lead sponsor
Hyloris Developments
Industry
Eligibility
18 Years to 99 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 18, 2026, 5:38 AM EDT